FSH

FSH is a hormone originating from the pituitary gland that plays a fundamental role in regulating reproductive functions. It supports follicle development in women and spermatogenesis in men. Its clinical measurement provides important diagnostic data in the evaluation of primary gonadal disorders.

FSH regulatory mechanisms define the feedback loops operating through the hypothalamic–pituitary axis. Deviations in these loops help distinguish ovarian failure, testicular dysfunction, or central axis pathologies.

The clinical interpretation of FSH levels examines the relationship between serum values, reproductive capacity, and hormonal status. High or low results support accurate classification when determining the source of endocrine disorders and in infertility investigations.

Indications for the FSH test include menstrual irregularities, suspected hypogonadism, and assisted reproductive treatment planning. Quantitative results facilitate the determination of treatment strategies and offer a comprehensive evaluation of reproductive physiology.

What Is FSH?

FSH (Follicle Stimulating Hormone) is a hormone secreted by the pituitary gland that regulates egg development in women and sperm production in men. In women, FSH levels provide important information about ovarian reserve and the menstrual cycle. A high FSH level may indicate decreased ovarian function. Therefore, it is one of the hormones frequently measured, especially in infertility research.

How does the body’s natural FSH balance work?

Your body is in constant ‘communication’ between the brain (hypothalamus and pituitary) and the ovaries to regulate the menstrual cycle. This complex and delicate system is called the ‘HPG axis.’

Here is how this communication works: The main control center in the brain (the hypothalamus) sends a signal called ‘GnRH.’ The rhythm of this signal—how often it is sent—is extremely important. When the signal is slow, the pituitary gland produces FSH (the egg-growing hormone). When it speeds up, it produces LH (the egg-releasing hormone).

At the beginning of the menstrual cycle, the rhythm is slow, and FSH is released. This FSH invites a group of candidate follicles to grow. As these follicles grow, they produce estrogen. When estrogen levels rise in the blood, a feedback signal is sent to the brain: “Okay, the egg is growing; we don’t need this much FSH anymore.”

The brain receives this signal, adjusts the GnRH rhythm, and decreases FSH production. Because of this natural ‘braking mechanism,’ only the strongest and fastest-growing follicle survives, while the others disappear. This is why normally only one egg develops during a menstrual cycle.

Why is this FSH balance different in women with Polycystic Ovary Syndrome (PCOS)?

In women with Polycystic Ovary Syndrome (PCOS), this communication between the brain and the ovaries works somewhat differently. GnRH signals from the brain are usually ‘too fast,’ and this rhythm does not change much.

This constantly fast rhythm causes the pituitary gland to produce LH instead of FSH. The LH/FSH ratio, which should normally be around 1:1, shifts in favor of LH in PCOS, often becoming 2:1 or even 3:1.

This high LH level increases androgen (male hormone) production in the ovaries. At the same time, relatively low FSH levels cause the follicles to begin growing but not mature. The follicles remain ‘stuck’ at a certain size, and ovulation does not occur. This also explains why women with PCOS are very sensitive to external FSH medications—because they already have many small follicles waiting for stimulation.

How does IVF treatment change this natural FSH balance?

The main goal in IVF treatment is to rescue and grow the other eggs that would normally be lost that month. The more mature eggs obtained, the more healthy embryos can be developed in the laboratory, which increases the chance of pregnancy.

To achieve this, we temporarily deactivate the body’s natural ‘braking mechanism.’ This is done using two main groups of medications.

Here are the steps:

• First, we temporarily stop the communication between the brain and the ovaries, or prevent early ovulation signals.
• Then, we take over the role of stimulating the ovaries using external FSH injections.
• When natural signals from the brain are suppressed (with GnRH agonists or antagonists), the ovaries no longer receive commands from the brain. At this point, we provide a higher and constant level of FSH through injections.

This high FSH level prevents the brain from hearing the “stop FSH production” signal sent by growing follicles (estrogen feedback). Because the FSH level does not decrease, all follicles that started growing that month survive and continue to grow together. This is called ‘widening the FSH window.’

What is the main role of FSH in egg and sperm production?

The role of FSH in reproductive health is crucial for both women and men.

In women, FSH selects a group of small follicles (antral follicles) each month and saves them from ‘apoptosis,’ a form of programmed cell death. It acts as a ‘lifeguard.’ Under the influence of FSH, granulosa cells inside these follicles activate a very important enzyme called ‘aromatase.’ This enzyme functions like a ‘factory,’ converting androgens (male hormones) into estrogen. The estrogen produced is necessary both for the final maturation stages of the egg and for thickening the uterine lining (endometrium) to prepare for a possible pregnancy.

In men, FSH is essential for sperm production (spermatogenesis). It directly affects ‘Sertoli cells,’ the ‘caretaker’ cells of sperm within the testes. FSH stimulates these cells to initiate and sustain sperm production. It also triggers Sertoli cells to produce ‘Androgen Binding Protein’ (ABP). This protein concentrates testosterone within the sperm-producing region. A high local testosterone concentration is essential for healthy sperm development.

Why is the FSH test performed to measure ovarian reserve?

The FSH test is one of the classic methods used to assess a woman’s ovarian reserve (egg quantity and potential). This test is called ‘basal FSH’ and is usually done on the 2nd, 3rd, or 4th day of the menstrual cycle.

This timing is very important. Because these days reflect a ‘baseline’ condition showing how much ‘support’ the ovaries request from the brain to begin a new cycle.

If ovarian reserve is diminished, the ovaries respond less effectively to the brain’s signals. In this case, the brain must ‘call louder,’ meaning it produces more FSH. A high FSH level (typically above 10–12 mIU/mL) on day 3 may indicate reduced ovarian reserve and increased effort by the brain.

How are FSH and Estrogen (E2) levels interpreted together?

Interpreting FSH alone can be misleading. It must always be evaluated together with the hormone ‘estrogen (E2).’ These two hormones exist in a balance.

In an ideal ovarian reserve, both FSH and E2 are expected to be low on day 3 of the menstrual cycle. This shows that the system is beginning the cycle in a ‘calm’ state.

However, sometimes FSH may appear ‘normal’ even when ovarian reserve is reduced. How does this happen? If the ovaries begin to grow a follicle earlier than expected (which is also a sign of low reserve), this follicle produces estrogen early. If we see an elevated E2 level on day 3 (for example above 60–80 pg/mL), this high estrogen may send a ‘braking’ signal to the brain and artificially suppress FSH, making it appear normal. This is called ‘masked’ diminished ovarian reserve.

Therefore, low FSH with high E2 is an important warning sign of declining ovarian reserve. A truly good result is low FSH and low E2.

Is the FSH test alone sufficient to assess ovarian reserve?

Although basal FSH testing provides valuable information, it is not considered a ‘gold standard’ reserve test. It is not sufficient alone.

There are several reasons:

• It may vary significantly from month to month.
• It may be easily masked by high estrogen levels.
• It measures the brain’s response, not the ovarian ‘egg supply,’ making it an indirect test.
• Its sensitivity is low; it often increases only after the reserve has already declined.

FSH levels may fluctuate month to month—one month 11, another month 8. This does not mean the reserve improved. Clinically, the ‘highest’ FSH value observed is usually considered. Because of these limitations, we now prioritize more reliable and modern tests to assess ovarian reserve.

How is modern FSH evaluation performed with AMH and AFC?

In modern IVF practice, two main tests are relied upon to predict how a patient will respond to treatment and to adjust medication doses:

• AMH (Anti-Müllerian Hormone): This hormone is secreted by the granulosa cells of the small ‘resting’ follicles in the ovaries. It provides clear, direct information about the ovarian ‘capital’ or the remaining follicle pool. Its greatest advantage is that it can be measured from blood on any day of the menstrual cycle and shows minimal month-to-month variation.
• AFC (Antral Follicle Count): This is a transvaginal ultrasound performed on day 2 or 3 of the menstrual cycle. During this exam, the number of small (2–10 mm) follicles ready to be stimulated that month is counted directly in both ovaries.

In current practice, AMH and AFC provide the most reliable information about egg quantity. A patient’s age is the most important determinant of egg quality. Basal FSH testing remains useful as an auxiliary and confirmatory test. This three-part evaluation forms the foundation of treatment planning.

Why is high-dose FSH not recommended in low ovarian reserve?

This has been a long-standing debate in IVF. For many years, in women with low ovarian reserve (low AMH, advanced age), very high doses of FSH (300 IU, 450 IU, even 600 IU) were used with the logic, “If the reserve is low, then give a stronger signal.”

However, recent large-scale high-quality clinical trials (Randomized Controlled Trials – RCTs) clearly showed that this approach does **not** work as expected.

These studies found the following: Increasing the dose from 150 IU to 450 IU may increase the number of eggs retrieved by only one or two. But it **does not** increase the ultimate goal of treatment—“the live birth rate.”

We now know that the main issue in low ovarian reserve is not a ‘lack of signal’ but the limited size of the ‘follicle pool.’ Giving excessively high medication to this small pool may reduce the quality of the few eggs available or negatively affect endometrial receptivity.

Therefore, current medical guidelines indicate that even in low-reserve patients, using more than 300 IU/day of FSH has no proven benefit and only increases cost. The important goal is to grow the few available eggs in the **best possible quality.**

What is the most important risk of FSH treatment (OHSS) and how is it prevented?

The most important and serious risk of IVF treatment is ‘Ovarian Hyperstimulation Syndrome’ (OHSS), in which the ovaries become overstimulated.

This occurs in women who respond excessively to FSH treatment (typically those with high ovarian reserve, PCOS, or younger patients) and develop many follicles. When ‘hCG’ (the trigger injection) is used to mature eggs, this hormone triggers the ovaries to release a substance called ‘VEGF.’ VEGF makes the blood vessels ‘leaky.’ Fluid escapes from the vessels into the abdomen and sometimes into the chest cavity, causing abdominal swelling, shortness of breath, nausea, and significantly enlarged ovaries.

Fortunately, with modern IVF techniques, OHSS can be almost completely prevented. Safety is always the top priority.

In high-risk patients (PCOS, high AMH, more than 20 follicles on ultrasound), the main strategies are:

• Starting treatment with a low and careful FSH dose.
• Always choosing the ‘Antagonist’ (short) protocol.
• Using a ‘GnRH Agonist’ trigger instead of hCG to mature the eggs (called ‘agonist triggering’).
• Using a ‘Freeze-All’ strategy when necessary.

The last two strategies are especially life-saving. Agonist triggering causes the body to release its own LH for only a short period (24–36 hours). This is enough to mature the eggs but not long enough to cause OHSS. In the ‘Freeze-All’ approach, no fresh embryo transfer is done that month. All healthy embryos are frozen. After the uterus recovers from the high hormone exposure and medication effects (1–2 months later), a frozen embryo is transferred in a more natural and safe cycle. This strategy also eliminates the risk of ‘late OHSS,’ which can be triggered by pregnancy.

Frequently Asked Questions